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http://www.biomedcentral.com/1472-6823/14/19RESEARCH ARTICLE Open AccessGenomic profiling of type-1 adult diabetic and
aged normoglycemic mouse liver
Flávia G Ghiraldini1*, André B Silveira2, Dirk A Kleinjan3, Nick Gilbert3 and Maria Luiza S Mello1Abstract
Background: Hyperglycemia induces chromatin remodeling with consequences on differential gene expression in
mouse hepatocytes, similar to what occurs during aging. The liver is the central organ for the regulation of glucose
homeostasis and xenobiotic and lipid metabolism and is affected by insulin signaling. The precise transcriptional
profiling of the type-1 diabetic liver and its comparison to aging have not been elucidated yet.
Methods: Here, we studied the differential genomic expression of mouse liver cells under adult hyperglycemic and
aged normoglycemic conditions using expression arrays.
Results: Differential gene expression involved in an increase in glucose and impaired lipid metabolism were
detected in the type-1 diabetic liver. In this regard, Ppargc1a presents an increased expression and is a key gene
that might be regulating both processes. The differential gene expression observed may also be associated with
hepatic steatosis in diabetic mouse liver, as a secondary disease. Similarly, middle-aged mice presented differential
expression of genes involved in glucose, lipid and xenobiotic metabolism. These genes could be associated with an
increase in polyploidy, but the consequences of differential expression were not as drastic as those observed in
diabetic animals.
Conclusions: Taken together, these findings provide new insights into gene expression profile changes in type-1
diabetic liver. Ppargc1a was found to be the key-gene that increases glucose metabolism and impairs lipid
metabolism impairment. The novel results reported here open new areas of investigation in diabetic research and
facilitate the development of new strategies for gene therapy.
Keywords: Type-1 diabetes, Aging, Liver, NOD mouse, Gene expressionBackground
Type-1 diabetes mellitus (T1DM) is an autoimmune dis-
ease caused by lymphocyte infiltration in the endocrine
pancreas leading to destruction of β-cells and conse-
quently, to hyperglycemia. Cardiovascular ailments, such
as heart attack and atherosclerosis [1], increased preva-
lence of pancreas, colon and liver cancer [2]; retinopa-
thies, nephropathies and skin conditions are examples of
secondary complications caused by hyperglycemia that
are accelerated when untreated. Aging shares a number
of risk factors with diabetes, such as insulin resistance,
higher cholesterol concentration and blood pressure,
leading to the theory that diabetes promotes a premature
and accelerated aging-like phenotype [3].* Correspondence: flaviaghi@gmail.com
1Department of Structural and Functional Biology, Institute of Biology,
University of Campinas (Unicamp), 13083-862 Campinas, SP, Brazil
Full list of author information is available at the end of the article
© 2014 Ghiraldini et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Although T1DM starts in the pancreas, the liver is a
central organ that regulates glucose homeostasis, xeno-
biotic metabolism and detoxification, steroid hormone
biosynthesis and degradation and lipid metabolism [4].
Hyperglycemia promotes chromatin remodeling and
increased polyploidy levels in hepatocytes from non-
obese diabetic (NOD) mice; these alterations are similar,
but not identical, to the changes observed in hepatocytes
from old mice [5]. Recently, it has been observed that
the alterations in chromatin organization that occur in
hepatocytes from hyperglycemic NOD mice might be or-
chestrated by the NAD+-dependent histone deacetylases
Sirt1 and Sirt6 [6]. Although these sirtuins were more
abundant in the NOD hyperglycemic mice, their activity
was unchanged because of limiting levels of NAD+,
which could promote differences in gene expression pat-
terns [6].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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investigate several organs in diabetic-related experi-
mental conditions, including the type-2 obese diabetic
mouse model (fat pads, liver and skeletal muscle) [7],
the type-1 diabetic NOD mouse model (pancreatic
lymph nodes, spleen and peripheral blood cells) [8] and
the streptozotocin-induced type-2 diabetic mouse model
(liver) [9,10]. However, there have been no studies inves-
tigating the gene expression profile of T1DM liver. In
this regard, the NOD mouse model presents an ad-
vantage over drug-induced diabetes models because the
disease in this mouse strain develops spontaneously;
additionally, there is no controversy over whether differ-
ences in gene expression in the liver are caused by
diabetes-induced agents. Moreover, given the similarities
between diabetes and aging in mouse hepatocytes, such
as increased polyploidy and chromatin remodeling, we
also investigated the effect of hyperglycemia and aging
on genomic expression patterns in mouse liver.
Methods
Animals
NOD/SHILTJ and Balb/c mice were maintained in an
animal care facility on a 12-h light/dark cycle and re-
ceived food and water ad libitum. The protocols involv-
ing animal care and use were conducted under the
guidance issued by the Medical Research Council in Re-
sponsibility in the Use of Animals for Medical Research
and Home Office Project License PPL 60/3785 (Edin-
burgh, UK) and by the Committee for Ethics in Animal
Use of the University of Campinas, Brazil (registration
no. 1608–1).
The glycemia levels of the animals were checked once
a week up to 24 h before they were euthanized. Blood
samples were obtained by caudal puncture and analyzed
using the automatic Accu-Check Performa glucose
meter (Roche Diagnostica do Brasil, Jaguare, Brazil). Gly-
cemia levels within the 90–100 mg/dL (5.00-5.55 mmol/
L) range were considered normal, and glycemia levels
over 500 mg/dL (27.5 mmol/L) for three weeks were
considered indicative of severe hyperglycemia. Four
mouse groups were used in this study: 1) three normo-
glycemic Balb/c young-adults (8-weeks-old); 2) three
normoglycemic Balb/c mice (47-weeks-old) 3) two se-
vere hyperglycemic NOD adults and a technical repli-
cate, and 4) normoglycemic NOD mice matched for age
to the diabetic groups. The technical replicate was ob-
tained mincing fragments of livers from two hypergly-
cemic NOD mice and processing them as a completely
independent sample. For the microarray validation by
qPCR five different animals of each group were used.
The animals were euthanized by cervical dislocation,
and their livers were removed and frozen in liquid nitro-
gen for molecular assays.RNA preparation
Total RNA was extracted from livers with Tri-Reagent
(Sigma®, St. Louis, EUA). Crude RNA samples were
On-Column purified with the RNeasy mini kit (Qiagen®,
Hilden, Germany) and analyzed with an Agilent 2100
BioAnalyzer (Agilent®, Santa Clara, USA) before being sub-
jected to microarray studies. Only samples with an RNA
Integrity Number (RIN) above 7 were further processed.
cRNA synthesis, labeling and hybridization
Total RNA (500 ng) was used to synthesize cRNA using
the Illumina TotalPrep RNA Amplification kit (Illumina®,
San Diego, USA) according to the manufacturer’s proto-
col. Hybridization, washing and scanning of Illumina
Whole Genome Mouse WG-6v2 Gene Expression Bead-
Chips were performed according to a standard protocol.
Microarray analysis
Raw signal intensity measurements, background correc-
tion and normalization of samples were processed with
the Illumina GenomeStudio software. Unpaired Limma
analyzes using the Limma package for the R-based Bio-
conductor software [11] were used to obtain differentially
expressed probesets with p < 0.05 and fold-change >2.0.
We obtained two separate differentially expressed gene
lists corresponding to the comparison of Balb/c young-
adults vs. aged Balb/c mice and the comparison of
normoglycemic NOD mice vs. severe hyperglycemic
NOD mice. The IPA software (Ingenuity Systems) was
used to functionally interpret the lists of differentially
expressed genes, and to analyze enrichment of gene
ontology groups and regulation of molecular networks.
The raw array data are available at the NCBI GEO data-
base with the accession number GSE50613.
Validation of microarray results by quantitative RT-PCR
Validation of differential gene expression was performed
for the Pck1, Igfbp1, Sirt1, Srebp1, Ppargc1a, Apoe and
Foxo1 genes by quantitative RT-PCR using the protocol
described above. Five animals were used for each experi-
mental condition (Additional file 1). Relative expression
was calculated using β-actin as the endogenous control.
Results
Of the 26,766 genes with established sequences available
on the Illumina® microarray chip, 219 were found to be
differentially expressed (FC > 2.0; p < 0.05) under hyper-
glycemic conditions in comparison to normoglycemic
conditions. Of these differentially expressed genes, 86
were up-regulated, and 133 genes were down-regulated.
The full list of differentially expressed genes is presented
in Additional file 2. The quantitative PCR using five bio-
logical replicates demonstrated the consistency of our
global expression profiling results (Additional file 1). We
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perglycemia were mainly involved in carbohydrate and
lipid metabolism (TR/RXR activation and PXR/RXR
activation pathways), as well as in inflammatory signal-
ing (crosstalk between dendritic cells and natural killers
cells; primary immunodeficiency signaling; caveolar-
mediated endocytosis signaling; cytotoxic T-lymphocyte-
mediated apoptosis of target cells) (Figure 1-A). Based
on which genes were differentially expressed and their
functions, a trend towards metabolic diseases such as
hyperglycemia (diabetes mellitus), hepatic steatosis and
hepatic cell death (Figure 1-B) could be identified.
From these data, Ppargc1a (peroxisome proliferator-
activated receptor gamma coactivator 1 alpha) was found
to be a key regulatory gene playing roles in two canonical
pathways that were differentially expressed under hyper-
glycemic conditions (high p-values): the TR/RXR activa-
tion (thyroid hormone receptor) and PXR/RXR activationFigure 1 Diabetic NOD mouse panel. (A) The most activated canonical p
that the association between the genes in the dataset and the canonical p
dataset that map to the pathway divided by the total number of genes tha
related to diseases found in the dataset. (C) Pregnane Receptor X and Thyr
indicate overexpression; genes in various shades of green indicate repressio(Pregnane X receptor) pathways (Figure 1-A). Ppargc1a
transcribes the transcription factor PGC-1α and is also
involved in other pathways with lower p-values. In these
pathways, Ppargc1a increased gluconeogenesis, carbo-
hydrate and xenobiotic metabolism and repressed lipolysis
(Figure 1-C). When the genes were analyzed from a func-
tional perspective, a general decrease in the expression
of genes related to lipid metabolism and molecular trans-
port and an increase in the expression of genes involved
with carbohydrate metabolism and detoxification were
detected; these pathways form a “metabolic network”
(Figure 2).
The middle-aged mice had 199 differentially expressed
genes compared to the young-adult mice; of these, 122
were up-regulated, and 77 were down-regulated. The
list of differentially expressed genes is presented in
Additional file 3. The global expression profiling and
qPCR results yielded similar trends, which can beathways in hyperglycemic NOD mice. –log(p-value), the probability
athway is due to chance alone; ratio, the number of genes from the
t map to the canonical pathway. (B) Differentially expressed genes
oid Receptor canonical pathways. Genes in various shades of red
n.
Figure 2 Metabolic network of diabetic NOD hepatocytes. Genes in shades of red indicate overexpression; genes in shades of green indicate
repression; genes in white were not found to be differentially expressed in our dataset. Arrow, direct relationship.
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ism and increased hepatocyte proliferation were hall-
marks of middle-aged mice (Figure 3-A). Among the
most significant canonical pathways found differentially
regulated in this experimental group, seven pathways in-
dicated up-regulation of genes related to cytochrome
P450 (Figure 3-B).
Considering all the genes that were differentially
expressed in both experimental groups, a total of 23
genes were shared between adult diabetic and middle-
aged normoglycemic mice (Figure 3-C). Twelve of the
shared genes were oppositely expressed in the two ex-
perimental groups, 11 were similarly expressed and were
involved in circadian rhythm, lipid and carbohydrate me-
tabolism (Figure 3-D). The 12 genes with inverted expres-
sion levels were related to several functions and could not
be grouped into functional categories (Figure 3-D).
Discussion
Type-1 diabetes mellitus is an autoimmune disease that
fundamentally produces an imbalance in carbohydrate
and lipid metabolism. The genes that were differentially
expressed in hyperglycemic animals played roles in the
regulation of both metabolic processes and inflammatory
signaling. Additionally, the transcription factor Ppargc1a
(PGC-1α) was a key upstream regulator. PGC-1α acts
with the histone deacetylase Sirt1 as a metabolic sensor
in hepatocytes and increases the expression of genesinvolved in the gluconeogenesis pathway [12]. This study
confirmed that PGC-1α was up-regulated in hyper-
glycemic mice, a finding that has been demonstrated
previously at the protein level [6], and highlighted Pck1
(phosphoenol pyruvate carboxykinase 1) and G6pc (glu-
cose −6-phosphatase) as targets of PGC-1α. Pck1 and
G6pc are glycolytic genes active in the thyroid receptor
pathway and induce gluconeogenesis [13].
PGC-1α also plays a role in lipid metabolism. In the
thyroid receptor canonical pathway, this protein induces
the expression of Srb1 (Scavenger receptor B member
1), which increases the uptake of cholesterol esters from
high-density lipoproteins (HDL) in the liver [14]. Fur-
thermore, PGC-1α decreases the expression of Srebp1
(Sterol regulatory element-binding transcription factor
1), inhibiting fatty acid synthesis; this phenomenon has
also been observed previously in Zucker diabetic fatty
rats [15].
In untreated cases of T1DM and T2DM, fatty liver dis-
ease is a common secondary complication [16]. This is
caused by an increased internalization of triglycerides in
the liver, enhanced hepatic fat synthesis and decreased
oxidation [17]. Indeed, we observed that the majority of
the differentially expressed genes related to lipid metab-
olism in the diabetic mouse liver transcribe molecules
that facilitate lipid uptake or regulate this process, such
as Npc1l1 (Niemann-Pick C1-like 1), Srebp1, Bhmt
(betaine-homocysteine S-methyltransferase) and Cav1
Figure 3 Middle-aged mice panel. (A) Differentially expressed genes related to altered biological functions in aging. Genes in shades of red
indicate overexpression; genes in shades of green indicate repression. (B) The most frequently altered biological function in middle-aged mice
hepatocytes. –log(p-value), the probability that the association between the genes in the dataset and the biological function is due to chance
alone. (C) Venn diagram of genes differentially regulated in both diabetic and middle-aged mouse hepatocytes. (D) List of genes with inverted
and similar expression between diabetic and middle-aged mice.
Ghiraldini et al. BMC Endocrine Disorders 2014, 14:19 Page 5 of 7
http://www.biomedcentral.com/1472-6823/14/19(Caveolin 1) [18-20]. The improper balance of genes re-
lated to lipid metabolism in diabetic NOD hepatocytes
may promote the development of hepatic steatosis as a
secondary complication, contributing to the aggravation
of T1DM [21]. However, other genes, such as Srebp1
and Fabp5 (fatty acid binding protein 5) involved in
the cholesterol biosynthesis and uptake, were down-
regulated. Therefore, although hepatic steatosis is sug-
gested, no morphological or anatomic alterations could
be identified in the samples analyzed. This might have
occurred because alterations in the mRNA level could
be still preliminary and might need longer period to fully
develop into different phenotypes.
Similar to diabetes, middle-aged mice presented differ-
entially expressed genes related to lipid metabolism.
When the biological functions of these genes wereanalyzed, an overall decrease in genes involved in lipid
metabolism was identified. The impaired lipid metabol-
ism could be linked to the increased polyploidy previ-
ously observed in diabetic and aged mice [5], where a
switch from oxidation of fatty acids to oxidation of glu-
cose occurs [17]. This confirm the hypothesis that poly-
ploidization is a response to high metabolic load and
stress injury [22]. Oxidative DNA injury, similarly to that
observed in T1DM [6] could impair proliferation, al-
though promoting mitogenic stimulation following poly-
ploidy [23]. The polyploidization process could enhance
cell survival pathways and differential energy consump-
tion in the liver preferring carbohydrates rather than
fatty acids for ATP production [24].
Indeed, the misbalance on lipid and carbohydrate me-
tabolism can be linked to increased production of
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untreated cases of T1DM [25]. The ROS generated by
excess glucose has been shown to increase DNA frag-
mentation and cell damage [6], which might contribute
to differentially regulate genes involved in stress re-
sponses and growth arrest that leads to hepatic cell
death. In fact, cytochrome P450 is involved in ROS for-
mation [26]. Increased ROS has been considered as one
of the hallmarks of aging and recently regarded as a
stress-triggered survival signal [27,28]. As the organism
gets older, ROS levels surpass the threshold that the cells
could attempt to maintain for normal function [27]. In
this study, two subunits of cytochrome P450 complex
were found overexpressed in T1DM mice, which might
contribute for the increase in DNA damage and be the
effector of possible phenotypical changes [6]. The key-
genes found here are responsible for the phase 1 of
xenobiotic metabolism, when an initial modification and
activation of typically lipophylic xenobiotics occur [29].
A counterbalance of four overexpressed and four down-
regulated subunits of the cytochrome P450 was observed
in aged mouse liver; however there were also 16 overex-
pressed genes related to stress response. This response
might also be a consequence of polyploidy because in-
creased expression of genes involved in stress responses
and chaperones occur as a physiological adaptation to
aging [17]. Several differentially expressed genes in mid-
dle aged-mice were related to hepatocyte proliferation.
Cdkn1a (p21), an inhibitor of cyclin-dependent kinases
[30], Egf (Epidermal growth factor) [31] and Mt1h (me-
talloproteinase 1), which is a negative growth regulator
[32], are genes involved in polyploidization and cell pro-
liferation and were differentially expressed. During the
polyploidization process the mouse hepatocytes may
enter in mitosis with incomplete cytokinesis and present
not only upregulated genes involved in cell proliferation
but also with stress response [24,33] similar to what was
observed in this study. This observation indicates a pos-
sible trend toward polyploidization during the aging
process, which is a well known phenomenon in mouse
liver [5,34-36].
In diabetic NOD mice, livers also presented differen-
tially expressed genes involved in immune signaling. The
canonical pathways related to inflammation and immune
response indicated a role for these genes in innate im-
munity, antigen presentation and immunodeficiency.
The crosstalk between the dendritic cells and natural
killer cells pathway has been related in other studies to
be one of the responsible alterations found in NOD mice
that could elicit T1DM [37,38]. In the liver of Type-1
diabetic NOD mouse, a small population of B220+-pre-
cursors dendritic cells with strong immune regulatory
properties is deleted, confirming that the liver may affect
the development of the autoimmunity of diabetes inNOD mice [37,38]. In general, most of the differentially
expressed genes in these mice were down-regulated, in-
cluding the bone marrow stromal cell antigen 2 (Bst2),
Fas ligand (Faslg) and interferon regulatory factor 7
(Irf7). A differential expression of these genes has also
been observed in Type-2 diabetic mouse hepatocytes [7].
It is known that with aging there is an accumulation of
pro-inflammatory tissue damage and that senescent cells
secrete pro-inflammatory cytokines, enhancing NF-kB
signaling [28]. In this study, middle-aged mice presented
12 genes differentially expressed that were involved with
inflammation, the most predominant class of which was
represented by chemokines. This indicates that both
type-1 diabetic and middle-aged mice presented a mis-
balance in inflammatory response, although during dia-
betes it was due to the auto-immune characteristic of
the disease.
Conclusions
Taken together, the present findings provide new in-
sights into gene expression profile changes in type-1 dia-
betic liver. These alterations have consequences for
several biological processes and key genes, such as
Ppargc1a. This particular gene increases glucose metab-
olism and impairs lipid metabolism, possibly leading to
hepatic steatosis. Moreover, the differential gene expres-
sion pattern observed in the middle-aged mouse liver
could be associated with polyploidization processes and
other physiological adaptations. The novel results re-
ported here highlighted PGC-1α as a key regulator in
diabetes and should open new areas of investigation in
diabetes research and even promote the development of
strategies for gene therapy.
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expression validation. (B) Gene expression validation.
Additional file 2: List of differentially expressed genes in diabetic
NOD mouse hepatocytes.
Additional file 3: List of differentially expressed genes in
middle-aged Balb/c mouse hepatocytes.
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